| I'm afraid you're misrepresenting this important area of research. > Psilocybin is being studied in conjunction with 10-20 therapy sessions For a quick reality check, you could take a look at Compass Pathways and their phase 1 & 2 clinical trial results [1][2]: > we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement for patients who received a single high dose of COMP360 psilocybin with psychological support That is a single dose along with a single therapy session, showing positive benefits lasting 12+ weeks. For treatment resistant depression (TRD), a notoriously difficult condition to cure and one that affects many people. There are literally no other drugs on the market that come close to the safety, efficacy, and durability profile that is being observed! Do you think the FDA granted breakthrough therapy status in 2018 because of some collective "utopian fantasy"? It's well known there are numerous indications for psychedelic assisted therapy showing great promise - from anxiety and addiction to end of life care [3]. It's not just psilocybin either, many of these psychedelic substances are pharmacologically related - so they act on similar receptors and areas of the brain, and thus have similar therapeutic profiles [4]. Let's be realistic. Your appeal to extremes is an uncharitable interpretation of my comment, and frankly your uninformed pessimism on this topic is a disservice to anyone interested in learning about or benefiting from these advances. [1] https://ir.compasspathways.com/news-releases/news-release-de... [2] https://ir.compasspathways.com/static-files/0f9fbce8-2619-43... [3] https://www.sciencedirect.com/science/article/pii/S009286742... [4] https://www.nature.com/articles/s41386-022-01297-2 |